At a glance
ClinicalIndex Comparison RecordN/ACompleted· 13 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
POST-MARKETING SURVEILLANCE STUDY TO OBSERVE INLYTA (REGISTERED) TREATMENT DOSING PATTERN, SAFETY AND EFFECTIVENESS IN TAIWAN REAL WORLD ROUTINE PRACTICE
In Brief
An observational study for Renal Cell Carcinoma. Completed, enrolled 13 participants.
Detailed Summary
This is a post-marketing Surveillance study to observe INLYTA® treatment dosing pattern, safety and effectiveness in Taiwan real world routine practice. The primary objective of this registry is to monitor the dose adjustment of INLYTA® in real world routine practice. The secondary objectives include safety profile, objective response rate, and progression-free rate in real world routine practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartDec 2015
Primary CompletionMay 2016
TodayJul 2026
First PostedAug 26, 2015
Enrollment StartDec 2, 2015
Primary CompletionMay 12, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 10.8 years ago